430 related articles for article (PubMed ID: 26519140)
1. Progress and challenges in viral vector manufacturing.
van der Loo JC; Wright JF
Hum Mol Genet; 2016 Apr; 25(R1):R42-52. PubMed ID: 26519140
[TBL] [Abstract][Full Text] [Related]
2. The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.
Felberbaum RS
Biotechnol J; 2015 May; 10(5):702-14. PubMed ID: 25800821
[TBL] [Abstract][Full Text] [Related]
3. Canadian Regulatory Framework and Regulatory Requirements for Cell and Gene Therapy Products.
Wang J; Griffiths E; Tounekti O; Nemec M; Deneault E; Lavoie JR; Ridgway A
Adv Exp Med Biol; 2023; 1430():91-116. PubMed ID: 37526844
[TBL] [Abstract][Full Text] [Related]
4. rAAV vector product characterization and stability studies.
Snyder RO; Audit M; Francis JD
Methods Mol Biol; 2011; 807():405-28. PubMed ID: 22034040
[TBL] [Abstract][Full Text] [Related]
5. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 3: Pig islet product manufacturing and release testing.
Korbutt GS
Xenotransplantation; 2009; 16(4):223-8. PubMed ID: 19799762
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in gene therapy research in India.
Selot R; Ghosh A
J Biosci; 2024; 49():. PubMed ID: 38384245
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated virus vectorology, manufacturing, and clinical applications.
Grieger JC; Samulski RJ
Methods Enzymol; 2012; 507():229-54. PubMed ID: 22365777
[TBL] [Abstract][Full Text] [Related]
8. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
[TBL] [Abstract][Full Text] [Related]
9. Regulatory Oversight of Cell and Gene Therapy Products in Canada.
Ridgway A; Agbanyo F; Wang J; Rosu-Myles M
Adv Exp Med Biol; 2015; 871():49-71. PubMed ID: 26374212
[TBL] [Abstract][Full Text] [Related]
10. Adeno-associated viral vectors for clinical gene transfer studies.
Snyder RO; Francis J
Curr Gene Ther; 2005 Jun; 5(3):311-21. PubMed ID: 15975008
[TBL] [Abstract][Full Text] [Related]
11. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
12. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
Myles L; Church TD
Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II Manufacture of Lentiviral Vectors Under GMP in an Academic Setting.
Dasgupta A; Tinch S; Szczur K; Ernst R; Shryock N; Kaylor C; Lewis K; Day E; Truong T; Swaney W
Methods Mol Biol; 2020; 2086():27-60. PubMed ID: 31707666
[TBL] [Abstract][Full Text] [Related]
14. The rapidly evolving state of gene therapy.
Gruntman AM; Flotte TR
FASEB J; 2018 Apr; 32(4):1733-1740. PubMed ID: 31282760
[TBL] [Abstract][Full Text] [Related]
15. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapy.
Thorne B; Takeya R; Vitelli F; Swanson X
Adv Biochem Eng Biotechnol; 2018; 165():351-399. PubMed ID: 28289769
[TBL] [Abstract][Full Text] [Related]
17. Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector.
Grieger JC; Soltys SM; Samulski RJ
Mol Ther; 2016 Feb; 24(2):287-297. PubMed ID: 26437810
[TBL] [Abstract][Full Text] [Related]
18. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
19. Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines.
Kotin RM; Snyder RO
Hum Gene Ther; 2017 Apr; 28(4):350-360. PubMed ID: 28351174
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
